Maffucci Syndrome

Rozeman, Leida B.; Schrage, Yvonne; Bovée, Judith V.M.G.; Hogendoorn, Pancras C.W.

doi:10.1007/978-3-211-69500-5_15

Cited by 2 publications

(3 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At a median follow-up of 17.4 months, rates of grade 3/4 AEs with intermittent dosing, particularly dabrafenib plus trametinib administered every third week, were lower (12%) than with continuous dosing (62%). Similar ORRs were observed regardless of dosing schedule, and the combined pembrolizumab plus dabrafenib plus trametinib arms numerically improved 18-month PFS and OS rates vs pembrolizumab alone . Thus, intermittent targeted therapy may increase the feasibility of combination with ICIs, although validation in larger studies is required.…”

Section: Looking To the Future: Ongoing Trials And Practical Consider...mentioning

confidence: 71%

“…Preclinical models suggest that intermittent dosing also offers the added benefit of delayed resistance . The phase 2 IMPemBra study (NCT02625337) is evaluating pembrolizumab plus intermittent or continuous dosing of dabrafenib plus trametinib . At a median follow-up of 17.4 months, rates of grade 3/4 AEs with intermittent dosing, particularly dabrafenib plus trametinib administered every third week, were lower (12%) than with continuous dosing (62%).…”

Section: Looking To the Future: Ongoing Trials And Practical Consider...mentioning

confidence: 99%

See 1 more Smart Citation

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma

et al. 2020

View full text Add to dashboard Cite

In recent years, the management of metastatic melanoma has been transformed by the emergence of immune checkpoint inhibitors and targeted therapies that significantly improve patient survival. The complementary response kinetics of these treatment approaches, supported by mechanistic evidence that targeted therapy affects immune aspects of the tumor microenvironment, suggest that the optimal combination or sequencing of immune checkpoint inhibitors and targeted therapy may provide additional clinical benefit.OBSERVATIONS Clinical responses to BRAF and/or MEK inhibitors are associated with immune changes within the tumor microenvironment that have the potential to increase the sensitivity of BRAF V600-mutant melanoma to immune checkpoint inhibitors. The combination of immune checkpoint inhibitors with targeted therapy may therefore increase duration of response, improve tumor control, extend survival, and increase the proportion of patients experiencing durable benefit. A targeted therapy-immune checkpoint inhibitor sequencing approach may also be supported by this evidence, but clinical questions regarding optimal timing, duration, and patient selection remain. CONCLUSIONS AND RELEVANCEThis review outlines the rationale and preclinical evidence that support immune checkpoint inhibitor plus targeted therapy combination and sequencing strategies in melanoma and highlights the results available to date from clinical trials exploring these approaches to treatment. Several late-stage trials are under way looking to answer open questions in this field and address the continuing debate surrounding up-front combination vs sequencing. As phase 3 data have begun to emerge, trial designs and available data from key studies are discussed in the context of their resultant implications for clinical practice.

show abstract

Section: Looking To the Future: Ongoing Trials And Practical Consider...mentioning

confidence: 71%

Section: Looking To the Future: Ongoing Trials And Practical Consider...mentioning

confidence: 99%

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Not only with communism, racial riot 13 May 1969 heighten the disunity in a multiethnic society. [25]. The Zone of Peace, Freedom and Neutrality (ZOPFAN) an excellence idea initiated by Tun Abdul Razak to keep the Southeast Asia free from any form or manner of interference by the outside powers.…”

Section: Overview Of Malaysia's Foreign Policymentioning

confidence: 99%

Malaysia- Indonesia Soft Power and Foreign Policy: Strengthening Bilateral Relations Through Internationalization of Higher Education

Wahab¹,

Harza²

2019

The International Conference on ASEAN 2019

View full text Add to dashboard Cite

There is continuity and change in Malaysia's foreign policy in the past six decades under the leadership of six Prime Ministers. The 'returns' of Mahathir as the 7 th Prime Minister of Malaysia might probably signal the changes in the contemporary Malaysia's foreign policy in responds to the globalization. One of the important sectors that actively embrace the positivity of globalization is higher education. There are a positive capability of higher education institutions (HEIs) as an instrument of Soft Power to strengthen the bilateral relations between Malaysia and Indonesia. With many unsettled security disputes and issues in between Malaysia and Indonesia, Mahathir and Jokowi might be prioritizing their Soft Power strategy. In the Malaysia context, growing numbers and the reputations of HEIs indicate the possibility that higher education to be integrate into enhancing and shaping the foreign policy. This paper highlights the potential of higher education institutions (HEIs) to be an effective platform to enriching the state's soft power and strengthening the bilateral relations between Malaysia and Indonesia through the internationalization of higher education.

show abstract

Maffucci Syndrome

Cited by 2 publications

References 51 publications

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma

Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma

Malaysia- Indonesia Soft Power and Foreign Policy: Strengthening Bilateral Relations Through Internationalization of Higher Education

Contact Info

Product

Resources

About